title: Reversal of docetaxel resistance with bevacizumab and thalidomide.
abstract: Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.
authors.affiliation: DDOP/OODP/CDER, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Yang-Min
authors.initials: YM
authors.lastname: Ning
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab; D013792:Thalidomide
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3942-50
references.pmid: 17606728
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):743-50
references.pmid: 15701864
references.citation: Clin Cancer Res. 2007 May 1;13(9):2804-10
references.pmid: 17473214
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2070-6
references.pmid: 20308663
references.citation: Cancer Ther. 2007;5A:151-160
references.pmid: 17712400
references.citation: Eur Urol. 2008 Nov;54(5):1089-94
references.pmid: 18276061
references.citation: J Clin Oncol. 1999 Nov;17(11):3461-7
references.pmid: 10550143
references.citation: Cancer. 2008 Feb 1;112(3):521-6
references.pmid: 18085595